193 results about "Pox virus" patented technology

The invention relates to the fields of biology, medicine and clinic. In particular to application of PAICS as a target spot in developing or screening reagents for preventing and / or treating orthopoxvirus infection, and application of inhibiting a synthetic pathway of purine nucleotide and / or inhibiting a metabolic pathway of folic acid in preparing reagents for treating and / or preventing orthopoxvirus infection diseases. In order to restrain the infection of orthopoxvirus, the inventor team uses a CRISPR / Cas9 technology to carry out generic genome screening on host cells infected by orthopoxvirus, determines a host-dependent gene PAICS gene in the orthopoxvirus infection process, and verifies and clarifies the virus-dependent mechanism of the gene; in order to deal with the global continuous orthopoxvirus infection problem, the invention plays an important role in the development and screening of future related prevention or treatment drugs, and also expands the new clinical application of existing drugs including methotrexate, mercaptopurine, mizoribine and the like.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.

The application relates to an antibody against monkeypox virus and a preparation method thereof, and the humanized monkeypox virus antibody H3-14A7 is obtained by screening memory B cells of a human antibody against H3 specific binding mouse. The H3-14A7 has the characteristics of strong monkeypox virus binding capacity, good in-vitro neutralization, large affinity and in-vivo protection.

The invention relates to the technical field of medicines, in particular to application of salinomycin in preparation of oral medicines for preventing or treating monkey pox virus (MPXV) infection. Salinomycin is a polyether antibiotic produced by actinomycetes. It is found for the first time that salinomycin can efficiently inhibit monkey pox virus infection on the cell culture level, and can significantly improve the survival rate of mice infected with monkey pox virus in small animal living bodies. More importantly, salinomycin can be administered by oral administration, has good bioavailability and safety, and provides a brand new treatment means for monkey pox virus infection. The medicinal value of salinomycin in resistance to monkey pox virus infection is reported for the first time at home and abroad, and the application prospect of salinomycin in the field of viral disease treatment is expanded.

The invention provides a novel vaccine based on an adenovirus vector and application thereof. According to the present invention, the suitable monkey pox virus gene is selected for the first time, and is efficiently integrated with the chimpanzee virus vector (AdC68) to prepare the ideal virus vaccine, and the ideal virus vaccine is suitable for nasal cavity immunization and muscle immunization, and has good nasal cavity immunization effect. The novel monkey pox vaccine can be effectively used for prevention and control of monkey pox virus and vaccinia virus infection, and the two types of viruses are considered.

The invention discloses an application of Arcyriaflavin A or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating monkey pox virus infection. The invention finds that the Arcyriaflavin A can obviously inhibit the replication of the monkey pox virus in a Vero cell, and the IC50 of the Arcyriaflavin A for inhibiting the Ib branch monkey pox virus and the IC50 of the Arcyriaflavin A for inhibiting the IIb branch monkey pox virus are 0.66 mu M and 0.96 mu M respectively. The invention also verifies that the Arcyriaflavin A has extremely low toxicity to Vero cells, and the toxicity CC50 of the Arcyriaflavin A to the cells is 41.51 mu M when the Arcyriaflavin A is used for inhibiting the proliferation of the monkey pox virus, so that the Arcyriaflavin A can be used for effectively inhibiting the replication of the monkey pox virus within the safe use range of the Arcyriaflavin A. The invention provides a new choice for the prevention and treatment of monkey pox, and has important significance for the prevention and treatment of monkey pox.

The present invention relates to a recombinant chimeric antigen targeting poxvirus (particularly monkeypox virus), a subunit vaccine thereof, and its application. The recombinant chimeric antigen of the present invention comprises two immunogens arranged in a specific manner: monkeypox virus A35 protein or its antigenic fragment (or its derivative peptide segment) and monkeypox virus M1 protein or its antigenic fragment (or its derivative peptide segment), which can stimulate immune responses against two infectious virus particles: intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV), thereby efficiently stimulating specific immune protection against monkeypox virus. In addition, the poxvirus vaccine of the present invention also has good safety, rapid responsiveness and production capacity support, and has excellent clinical application prospects.

The invention provides a novel bovine nodular skin disease virus LSDV-125 strain and application thereof in vaccine preparation, and belongs to the technical field of virology. The problem that a novel vaccine strain which is clear in genetic background, stably weakened in virulence and capable of inducing broad-spectrum immune response is urgently needed is solved. The invention relates to a sheep pox virus strain, in particular to a sheep pox virus LSDV-125 which is named sheep pox virus LSDV-HLJ-2023, has the preservation number of CCTCC (China Center for Type Culture Collection) NO: V202537, and is preserved in China Center for Type Culture Collection on May 13, 2025. The method is mainly used for developing efficient and safe attenuated live vaccines.

The invention discloses a method for detecting high sensitivity of monkey pox virus by a one-pot method RPA-CRISPR based on temperature control, and the method comprises the following steps: establishing a temperature-controlled RPA and CRISPR-Cas12b combined detection method, which is called as CRATS for short, by utilizing the reaction temperature difference between RPA amplification and CRISPR-Cas12b cutting; the reaction process in a tube system is regulated and controlled by stages through a temperature switching strategy: target amplification is completed at 37 DEG C firstly, then the temperature is raised to 60 DEG C, Cas12b cutting is started, so that sequential separation of amplification and cutting reactions is realized, and finally detection is realized through a fluorescence signal released by molecular beacon breakage. The problem that Cas enzyme cutting activity interferes with the amplification process in a traditional one-pot method reaction is solved, the detection sensitivity and specificity are improved, and a new technical means is provided for on-site rapid detection of the monkey pox virus.

The present invention relates to specific monoclonal antibodies and their applications. The amino acid sequence of the light chain CDR1 of the monoclonal antibody is shown in SEQ ID No. 1, the amino acid sequence of CDR2 is shown in SEQ ID No. 2, and the amino acid sequence of CDR3 is shown in SEQ ID No. 3; the amino acid sequence of the heavy chain CDR1 of the monoclonal antibody is shown in SEQ ID No. 4, the amino acid sequence of CDR2 is shown in SEQ ID No. 5, and the amino acid sequence of CDR3 is shown in SEQ ID No. 6. The present invention uses recombinant monkeypox virus surface protein E8L as an antigen. The screened monoclonal antibodies have good affinity for the recombinant monkeypox virus surface protein E8L at the molecular and cellular levels, can significantly inhibit the infection efficiency of VACV replication-deficient strains in VERO cells, and have good in vitro neutralization effect against monkeypox virus.

The invention relates to the field of biological medicine, in particular to application of disulram in preparation of an orthopoxvirus inhibitor, the disulram is specifically combined with palmitic acid on MPXV gp045 membrane protein to show a remarkable inhibition effect on orthopoxviruses, and when IC50 of the disulram is 825nM, diffusion of the orthopoxviruses can be remarkably inhibited; in HeLa and Huh7.5. 1 cells, when IC50 is 3022nM and 7125nM respectively, formation of EEV can be remarkably inhibited, so that further transmission of orthopoxvirus is prevented, and a more comprehensive intervention means is provided for treatment of orthopoxvirus resistance.

This invention relates to monoclonal antibodies for detecting A35R protein and their applications. This invention screened six antibodies, including antibody 4E7, antibody 11G12, antibody 6F10, antibody 6C11, antibody 18C3, and antibody 23A7. Specifically, this invention discloses the amino acid sequences of the heavy chain variable region and the light chain variable region of the above antibodies, as well as the amino acid sequences of their complementarity-determining regions and framework regions. Antibodies 4E7 and 11G12 can bind not only to the A35R-MPXV protein but also to its homologs A35R-CPXV, A35R-VTT8, and A35R-Variola. Antibodies 6F10, 6C11, 23A7, and 18C3 can specifically recognize the A35R-MPXV protein. The monoclonal antibodies described above all exhibit high binding capacity to the A35R protein, making them suitable for the sensitive and specific detection and prevention of monkeypox virus A35R protein. They can also be used clinically for the diagnosis and treatment of monkeypox virus infection-related diseases.

The present invention relates to 2'-fluoro-6'-methylene carbocyclic nucleosides and nucleotides, pharmaceutical compositions containing these nucleosides and nucleotides, and their use in the treatment or prophylaxis of poxvirus infections and secondary disease states and conditions thereof.

Provided herein are methods of producing immunoglobulin Y (IgY) antibodies against monkeypox virus. The method includes immunizing hens with a peptide encoding at least one immunogenic domain of A29 fusion protein from the monkeypox virus and isolating the IgY antibodies against the A29 fusion protein from yolks of eggs laid by the immunized hens. Pharmaceutical compositions containing the IgY antibodies and methods of inhibiting or treating monkeypox virus infection are also provided.

This application discloses antibodies against monkeypox virus, their preparation methods, and applications. Specifically, this application discloses eight antibodies (A35R-9E4, A35R-9F8, A35R-10C4, A35R-10D5, A35R-10E7, A35R-10H6, A35R-18E2, and A35R-18H2) that have excellent affinity for the monkeypox virus A35R protein, and that they exhibit good neutralizing activity and certain in vivo protective effects.

The invention discloses a primer probe composition for detecting measles, parotitis, rubella and varicella virus nucleic acid and application, and belongs to the technical field of virus nucleic acid detection. The invention protects the real-time fluorescent PCR detection primer and probe composition for simultaneously or respectively detecting measles, parotitis, rubella and varicella viruses and different subtype strains, and plays a positive role in respectively or simultaneously performing clinical detection and prevention and diagnosis on different strains of several viruses. The detection method disclosed by the invention is simple, time-saving and labor-saving, wide in application range and convenient to use, and measles, rubella, parotitis and varicella viruses and different strains can be rapidly detected at the same time by amplifying a PCR reaction once. The primer probe composition provided by the invention is high in detection sensitivity, strong in specificity and good in repeatability, can realize rapid differential diagnosis on clinical samples, enables different patients to obtain timely targeted prevention and treatment, and has important significance for development of quadruple vaccines.

Provided are a primer-probe combination for real-time quantitative PCR, a related kit, and a method for using primers to measure the titers of measles, mumps and varicella virus pathogens. The method is applicable to clinical and laboratory detection, is fast and convenient, and has high sensitivity.

The present invention belongs to the field of biopharmaceutical technology, and specifically relates to a monoclonal antibody that binds to the monkeypox virus B6R protein and its application. The antibody is a combination of any one or more of B6R-B5, B6R-F6, and B6R-F11, and the B6R-B5, B6R-F6, and B6R-F11 all contain a heavy chain variable region and a light chain variable region, the heavy chain variable region having three heavy chain CDRs, and the light chain variable region having three light chain CDRs. The present invention provides three groups of monoclonal antibodies with excellent affinity for monkeypox virus B6R and disclosed sequences of each heavy chain and light chain variable region, providing technical support for the preparation of monkeypox virus detection and diagnostic reagents, and is expected to be developed into a specialized product for screening and diagnosis of monkeypox virus, with high application value for the prevention, control, and treatment of monkeypox virus.

The present disclosure relates to smallpox vaccines and stem cells for treating diseases. Described herein are methods and compositions for treating an inflammatory disease or an infectious disease in a subject in need thereof by administering a poxvirus and a stem cell to the subject, wherein the disease is not a cancer. For example, the disease can be a chronic inflammatory disease (e.g., an autoimmune disease).

The application belongs to the technical field of image recognition, and discloses a monkeypox virus classification method and system based on image comparison and a storage medium, which comprises an individual reference modeling module, collects normal skin and initial lesion images of a healthy side of a patient, generates a healthy texture template and an initial lesion reference library, performs gray scale normalization on the healthy texture template and the initial lesion reference library through adaptive histogram stretching, and outputs a comparison reference image group; a symptom density quantification module, acquires a current monitoring image of the patient, segments a lesion area in combination with the comparison reference image group, extracts layered features of the lesion area to generate a three-dimensional symptom density vector, extracts texture roughness of a surface of the lesion area, and constitutes a lesion quantification data set; the accuracy of disease monitoring is improved, and a clinical nursing process is optimized.

The present application relates to a kind of artificially synthesized recombinant monoclonal antibody with human antibody amino acid sequence as framework.The present application uses phage display technology, and obtains one monoclonal antibody H11 from Tomlinson I+J phage library, and these new amino acid sequences constitute CDR1, CDR2 and CDR3 region, can be combined with A29L protein specific binding.It shows good stability, high specificity and high affinity and other characteristics, provide tool support for subsequent monkeypox virus diagnosis and detection with A29L protein as target.

The invention relates to the field of antibody engineering, in particular to a monoclonal antibody specifically targeting a monkey pox virus and application of the monoclonal antibody. According to the invention, by screening mouse memory B cells specifically combined with monkey pox virus envelope protein A35R, monkey pox virus antibodies 1H4, 3H3, 3H6, 13H1 and 17H1 with high neutralization activity are obtained. Wherein 17H1 has excellent affinity and neutralizing efficacy on monkey pox virus and has a strong in-vivo protection effect, and 100% of survival rate of challenged mice is achieved in prevention and treatment experiments. The sequence of the antibody is completely different from that of an existing monkey pox virus antibody, and a new candidate product is provided for detection, diagnosis, prevention and treatment of the monkey pox virus.

Disclosed are an assay, method, and kit for detecting a monkeypox virus (MPXV) and the application thereof. The assay may be used alone or in combination with another assay or assays. The method of using and kit includes a composition used for detecting MPXV, wherein the composition is composed of a primer pair and a probe. The primer pair is composed of two single-stranded nucleic acid molecules shown in the first sequence and the second sequence in a sequence list, and the sequence of the probe is the third sequence in the sequence list. The kit is used for detecting MPXV, and has advantages of providing real-time screening of MPXV reducing cross-reaction to other pox diseases, and increasing specificity to MPXV for disease prevention and improvement of public health.

The present invention specifically relates to a monoclonal antibody 2D7, which is directed against the monkeypox virus A35R protein. The present invention first repeats and concatenates the MPXV A35S gene sequence via a linker (Gly4Ser)3, and then uses this as an immunogen to screen and obtain the monoclonal antibody 2D7, which is directed against the monkeypox virus A35R protein. The heavy chain of this monoclonal antibody comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 1 to 3, and the light chain comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 4 to 6. Further experimental studies have revealed that it has good specificity, high binding activity and affinity, and can be used in colloidal gold rapid detection kits, laying the foundation for the detection of monkeypox virus A35R protein.

The present invention is related to method of preparing a gain-of-function mutation in poxvirus, like buffalopox virus (BPXV) by long-term propagating it in the presence of methyltransferase inhibitor like 3-Deazaneplanocin A (DZNep), which results in generation of viral 2'O-MTAse (VP39) mutant with a single point mutation (M236I). The resultant mutant has the following characteristics: (a) M236I mutation of 2'O-MTAse increases the cap-1 markings on viral mRNA; (b) The 2'O-MTAse mutant virus had hyperactive 2'O-MTAse and exhibited enhanced stability and translational efficiency of its mRNA; (c) The capping (cap1) performed by the mutant viral 2'O-MTAse (VP39) results in higher viral protein production, as compared to the wild type VP39 and (d) Mutant virus replicated at higher viral titer than the wild-type virus.

The present application relates to the technical field of biotechnology, in particular to a monoclonal antibody against A29L protein of monkeypox virus and application thereof. The present application prepares the monoclonal antibody against A29L protein of monkeypox virus, and through optimization of antibody screening and expression technology, the antibody with high affinity and high specificity is screened, and then a new tool is provided for rapid detection, effective neutralization and treatment of monkeypox virus, and an important immunological basis is provided for vaccine research and development and treatment scheme design of monkeypox virus.

This invention discloses a high-throughput screening method for monkeypox virus (MPXV) N7-methyltransferase (N7-MTase) inhibitors based on fluorescence polarization technology and its application. This method uses MPXV E1... CTD Using the / E12 protein complex as a target, and leveraging the specific binding characteristic of the fluorescent probe FL-NAH to the target catalytic center, small molecule inhibitors that competitively bind to the SAM binding site are screened by monitoring changes in fluorescence polarization signals. This invention yielded a series of candidate compounds with significant inhibitory activity. Experiments demonstrated that these inhibitors exhibit strong inhibitory effects on MPXV N7-MTase, with a biochemical IC50 level of [missing information]. 50 Preferably, the concentration can reach 4.65 μM; at the cellular level, the compound exhibits a clear attenuation effect against poxviruses, with an EC50 value of [missing value]. 50 The range is up to 46.75 μM, and it has low cytotoxicity (CC). 50 >200 μM).

The present invention is directed to a method for detecting the presence or absence of monkeypox virus (MPXV) in a biological sample, the method comprising: a) contacting the sample or nucleic acid extracted from said sample with reagents and an oligonucleotide combination capable of amplifying a target region of a monkeypox viral genome, wherein said oligonucleotide combination is selected from the group consisting of: i) a B7R oligonucleotide primer set specific for amplifying a target sequence in the B7R gene of the MPXV genome generating an MPXV amplification product comprising the sequence of SEQ ID NO:65; and ii) a G2R oligonucleotide primer set specific for amplifying a target sequence in the G2R gene of the MPXV genome generating an MPXV amplification product comprising the sequence of SEQ ID NO:63; b) performing an in vitro nucleic acid amplification reaction, wherein any MPXV nucleic acid present in the sample is used as a template to generate the MPXV amplification product corresponding to the oligonucleotide combination of i) or ii); and c) detecting the presence or absence of the MPXV amplification product generated in step b), wherein the presence of the MPXV amplification product is indicative of the presence of MPXV in the biological sample. The present invention also provides oligonucleotides which can be used in the method of the invention as primers and probes.

The application belongs to the technical field of virus detection, and discloses a sheep disease virus multiplex PCR detection primer, method and application. The base sequence of the primer FMDV-F of the sheep foot-and-mouth disease virus is SEQ ID NO:1, the base sequence of the primer FMDV-R is SEQ ID NO:2; the base sequence of the primer ORFV-F of the sheep orf virus is SEQ ID NO:3, the base sequence of the primer ORFV-R is SEQ ID NO:4; the base sequence of the primer GTPV-F of the goat pox virus is SEQ ID NO:5, and the base sequence of the primer GTPV-R is SEQ ID NO:6. The application optimizes the multiplex PCR, determines the optimal reaction system and the optimal reaction procedure, and can accurately detect single or mixed infection of the sheep foot-and-mouth disease virus, the sheep orf virus and the goat pox virus, and has an important role in epidemiological investigation and epidemic disease prevention and control.